Khiron Life Sciences (TSXV: KHRN) (OTCQB: KHRNF) (Frankfurt: A2JMZC) has announced that Mark Monaghan has resigned as a director of the company and his position will be filled by Deborah Rosati.

The changes are effective immediately, according to a company statement.

Rosati has over 30 years of experience in managing high-growth companies. She is a corporate director, entrepreneur, and FCPA with more than 30 years of experience, including in consumer, cannabis, private equity and venture capital. He has advised over 20 private companies on business strategy and financial growth.

Rosati is a past board member and chair of the audit committee at MedReleaf, the founder and CEO of Women Get On Board, which connects, promotes and empowers women to corporate boards.

“Her experience in finance, corporate strategy, mergers and acquisitions, and governance will be a tremendous asset for the Company. As we continue to expand our operations and execute on our business strategy, Deborah’s appointment to our Board is a valued addition,” Khiron CEO Alvaro Torres stated.